By Deena Beasley May 5 (Reuters) - Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Meeting UNAIDS’ “95/95/95” targets for 2025—95% of people with HIV knowing their status, 95% of those who know their status on treatment, and 95% of people on treatment having a suppressed viral ...

Lenacapavir, a twice-yearly injectable antiretroviral, demonstrated 100% effectiveness for preventing HIV acquisition in a large study of young cisgender women in Africa, Gilead Sciences announced ...

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...

Gilead Sciences' twice-yearly HIV prevention injection Yeztugo has gained users since its June launch, but adoption is slowed by insurance coverage gaps, patient preference for pills, and concerns ...

Learning the best type of HIV prevention for those at highest risk can start with conversations about their options, writes Zandraetta Tims-Cook, MD, MPH, AAHIVS In the US, we have made remarkable ...

Did you know that there is a medication referred to as the birth control pill for HIV? HIV Pre-Exposure Prophylaxis (PrEP) is a pill that may cause a revolution in HIV prevention. If taken daily, ...

A twice yearly injection that is highly effective in preventing HIV transmission could dramatically reduce infections and save lives — if the people who would most benefit from the drug can obtain it, ...

The Illinois Department of Public Health has issued a standing order that will allow residents to obtain the HIV preventive medication known as PrEP (pre-exposure prophylaxis) directly from a ...